Oppenheimer Asset Management Inc. Has $2.95 Million Holdings in Edwards Lifesciences Corporation $EW

Oppenheimer Asset Management Inc. grew its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 57.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,880 shares of the medical research company’s stock after buying an additional 13,820 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Edwards Lifesciences were worth $2,946,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Norges Bank bought a new position in Edwards Lifesciences during the second quarter valued at approximately $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after acquiring an additional 4,805,819 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Edwards Lifesciences by 127.5% during the 2nd quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after purchasing an additional 3,864,908 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Edwards Lifesciences by 19.6% during the 3rd quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock worth $1,085,574,000 after purchasing an additional 2,287,783 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Edwards Lifesciences by 8.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock valued at $1,478,425,000 after purchasing an additional 1,423,365 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE:EW opened at $79.29 on Thursday. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a market cap of $46.01 billion, a PE ratio of 43.33, a price-to-earnings-growth ratio of 2.98 and a beta of 0.94. Edwards Lifesciences Corporation has a 12 month low of $65.94 and a 12 month high of $87.89. The company’s 50-day moving average price is $83.73 and its two-hundred day moving average price is $81.13.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Company-level outlook: Edwards raised its 2026 profit outlook and told investors it expects demand to remain robust for its artificial heart valves and structural‑heart devices, a primary reason shares rallied after hours. Reuters: Forecasts 2026 profit above estimates
• Positive Sentiment: Quarterly guidance beat: EW provided Q1 2026 EPS guidance of $0.700–$0.760 (above consensus ~ $0.69) and reiterated revenue guidance, which helped calm near‑term uncertainty. Business Wire: Q4 results and guidance
• Positive Sentiment: Revenue momentum: Q4 sales grew ~13.3% YoY, led by TAVR (double‑digit growth) and strong TMTT performance — evidence of sustained demand for core products. Zacks: Revenues up Y/Y; TAVR/TMTT strength
• Positive Sentiment: Analyst support: Several firms reiterated Buy/Overweight ratings and raised targets (Wells Fargo to $100; BTIG reaffirmed $103; other firms reiterated conviction), boosting sentiment and providing upside to estimates. TipRanks: Multiple buy ratings and analysis
• Neutral Sentiment: Options/short-term trade view: Some commentators see the post‑earnings weakness as a contrarian/options opportunity for bulls now that key earnings uncertainty is cleared. Benzinga: Options contrarian trade
• Neutral Sentiment: Earnings call detail available: Management commentary from the Q4 call/earnings transcript provides more color on margin drivers and product cadence for investors who want to dig deeper. Seeking Alpha: Q4 earnings call transcript
• Negative Sentiment: Profitability pressures and EPS miss: Adjusted EPS (~$0.58) missed consensus and GAAP profitability showed sizeable year‑over‑year declines (operating and net income hit), reflecting margin headwinds and one‑time items that investors should watch. Quiver: GAAP profit and EPS pressure

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 7,700 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $84.47, for a total transaction of $650,419.00. Following the sale, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,370,184.06. This represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 43,804 shares of company stock valued at $3,699,082. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Raymond James Financial raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price objective for the company in a research note on Monday, November 3rd. Wells Fargo & Company raised their target price on Edwards Lifesciences from $96.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday. National Bank Financial set a $92.00 price target on Edwards Lifesciences in a research note on Friday, October 31st. Royal Bank Of Canada boosted their target price on Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. Finally, Citigroup restated a “buy” rating and set a $101.00 price objective (up previously from $96.00) on shares of Edwards Lifesciences in a report on Thursday, December 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and an average target price of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.